Validation of global item for assessing impact on quality of life of patients with hidradenitis suppurativa*
| Autor: | Melissa Butt, Joslyn S. Kirby, Solveig Esmann, L. Thorlacius, Gregor B.E. Jemec, B. Hereford, T. King, Jerry Tan, B. Villumsen, Amit Garg, John R. Ingram |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Adult
medicine.medical_specialty Intraclass correlation Pain Dermatology Severity of Illness Index Article 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Quality of life Rating scale Severity of illness medicine Humans Hidradenitis suppurativa business.industry Reproducibility of Results Dermatology Life Quality Index medicine.disease Confidence interval Hidradenitis Suppurativa Cross-Sectional Studies Convergent validity Quality of Life Physical therapy business |
| Zdroj: | Kirby, J S, Hereford, B, Thorlacius, L, Villumsen, B, Ingram, J R, Garg, A, Butt, M, Esmann, S, King, T, Tan, J & Jemec, G B E 2021, ' Validation of global item for assessing impact on quality of life of patients with hidradenitis suppurativa* ', British Journal of Dermatology, vol. 184, no. 4, pp. 681-687 . https://doi.org/10.1111/bjd.19344 Br J Dermatol |
| Popis: | BACKGROUND: Hidradenitis suppurativa (HS) is a chronic inflammatory disease that is not well understood. The HS core outcome set calls for a patient global assessment (PtGA), for which measures are limited. OBJECTIVES: Our aim is to assess the validity, reliability, and responsiveness of a candidate single-item PtGA for HS-specific health-related quality of life (HRQOL). METHODS: Cognitive debriefing interviews were conducted with HS patients in Denmark (DK) and the United States (US). Field testing was conducted via a cross-sectional observational study with adults with HS in the US and DK. The candidate PtGA item, demographic items, and multiple patient-reported scales including the Hidradenitis Suppurativa Quality of Life (HiSQOL), Dermatology Life Quality Index (DLQI), numerical rating scale (NRS) for pain were concurrently administered to evaluate convergent and known-groups validity. The scales with a single-item assessment of change were administered again 24-72 hours later to evaluate reliability and responsiveness. RESULTS: After cognitive debriefing, the candidate PtGA for HS-specific HRQOL was finalized with five response levels. Convergent validity of the PtGA was supported with significant correlations with the HiSQOL score r = 0.79 [95CI: 0.75-0.82] and DLQI (r = 0.78, [95CI: 0.74-0.82]). The PtGA displayed known-groups validity with the DLQI score bands based on significance of an analysis of variance (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|